Page last updated: 2024-12-11
neotame
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Occurs in Manufacturing
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
neotame: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
neotame : A dipeptide composed of N-(3,3-dimethylbutyl)-L-aspartic acid and methyl L-phenylalanate units joined by a peptide linkage. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9810996 |
| CHEMBL ID | 3718532 |
| CHEBI ID | 83503 |
| SCHEMBL ID | 4311 |
| MeSH ID | M0357909 |
Synonyms (51)
| Synonym |
|---|
| neotame [nf] |
| hsdb 7965 |
| l-phenylalanine, n-(3,3-dimethylbutyl)-l-alpha-aspartyl-, 2-methyl ester |
| unii-vj597d52ex |
| vj597d52ex , |
| neotame |
| n-(n-(3,3-dimethylbutyl)-l-alpha-aspartyl)-l-phenylalanine 1-methyl ester |
| nc 00723 |
| (3s)-4-[[(1s)-1-benzyl-2-methoxy-2-oxo-ethyl]amino]-3-(3,3-dimethylbutylamino)-4-oxo-butanoic acid |
| 165450-17-9 |
| A810640 |
| (s)-3-((3,3-dimethylbutyl)amino)-4-(((s)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-4-oxobutanoic ac |
| S4442 |
| BCP9000982 |
| (s)-3-((3,3-dimethylbutyl)amino)-4-(((s)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-4-oxobutanoic acid |
| BCP0726000005 |
| AM84564 |
| (3s)-3-[(3,3-dimethylbutyl)amino]-3-{[(2s)-1-methoxy-1-oxo-3-phenylpropan-2-yl]carbamoyl}propanoic acid |
| neotame [mi] |
| neotame [mart.] |
| nc-00723 |
| n-(n-(3,3-dimethylbutyl)-l-.alpha.-aspartyl)-l-phenylalanine 1-methyl ester |
| mirasee 200 |
| neotame [fhfi] |
| l-phenylalanine, n-(n-(3,3-dimethylbutyl)-l-.alpha.-aspartyl)-1-methyl ester |
| e 961 |
| neotame [fcc] |
| ins-961 |
| ins no.961 |
| neotame [ii] |
| neotame [usp-rs] |
| e-961 |
| neotame [inci] |
| SCHEMBL4311 |
| methyl n-(3,3-dimethylbutyl)-l-alpha-aspartyl-l-phenylalaninate |
| n-[n-(3,3-dimethylbutyl)-l-alpha-aspartyl]-l-phenylalanine methyl ester |
| CHEBI:83503 |
| DTXSID50167950 |
| CHEMBL3718532 |
| GS-3213 |
| neotame, analytical standard |
| J-010204 |
| (3s)-3-(3,3-dimethylbutylamino)-4-[[(2s)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid |
| CS-W011769 |
| Q415698 |
| HLIAVLHNDJUHFG-HOTGVXAUSA-N |
| AKOS016842430 |
| HY-W011053 |
| (s)-3-((3,3-dimethylbutyl)amino)-4-(((s)-1-methoxy-1-oxo-3-phenylpropan-2-yl)amino)-4-oxobutanoicacid |
| neotame 1000 microg/ml in water |
| N1112 |
Research Excerpts
Overview
Neotame (NEO) is a new artificial sweetener approved as a food additive in many countries. Neotame is a relatively new low-caloric and high-intensity artificialSweetener.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Neotame is a relatively new low-caloric and high-intensity artificial sweetener, approved by FDA in 2002." | ( Effects of the Artificial Sweetener Neotame on the Gut Microbiome and Fecal Metabolites in Mice. Bian, X; Chi, L; Gao, B; Lai, Y; Lu, K; Ru, H; Tu, P, 2018) | 1.48 |
| "Neotame (NEO) is a new artificial sweetener approved as a food additive in many countries. " | ( Determination of neotame in non-alcoholic beverage by capillary zone electrophoresis. Gao, Y; Hu, F; Liu, H; Luan, F; Xu, L, 2013) | 2.17 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " In definitive safety studies, there were no adverse findings related to neotame treatment from clinical observations, physical examinations, water consumption, or clinical pathology evaluations; nor was there morbidity, mortality, organ toxicity, macroscopic or microscopic postmortem findings." | ( Food consumption and body weight changes with neotame, a new sweetener with intense taste: differentiating effects of palatability from toxicity in dietary safety studies. Comer, CP; Mayhew, DA; Stargel, WW, 2003) | 0.81 |
| " This study investigates the question of whether the changes in BWG were adverse or secondary to small, long-term decrements in FC." | ( Long-term food consumption and body weight changes in neotame safety studies are consistent with the allometric relationship observed for other sweeteners and during dietary restrictions. Blackburn, GL; Comer, CP; Flamm, WG; Mayhew, DA; Stargel, WW, 2003) | 0.57 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Concentrations were increased as animals grew to maintain constant dosing on a "mg/kg bw/day" basis." | ( Food consumption and body weight changes with neotame, a new sweetener with intense taste: differentiating effects of palatability from toxicity in dietary safety studies. Comer, CP; Mayhew, DA; Stargel, WW, 2003) | 0.58 |
| " Altogether, our findings indicate that denatonium stimulates CASR by shifting a dose-response curve for the principal CASR agonist Ca(2+) to lower concentrations." | ( Stimulation of the extracellular Ca²⁺-sensing receptor by denatonium. Bystrova, MF; Churbanov, GD; Kolesnikov, SS; Rogachevskaja, OA; Romanov, RA, 2011) | 0.37 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]